Company Profile
Adaptive Biotechnologies Stock Price, News & Analysis
- Ticker:
- ADPT
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
23.60 USD (-4.07%)
Close
Last updated: August 6, 2026
2.42B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ADPT closed down 4.07% at $23.60. No new same-company headline was identified in the current news window.
Company overview
Adaptive Immune-System Platform
Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics.
Minimal Residual Disease
The company’s commercial MRD business is led by clonoSEQ, a sequencing-based test used to detect and monitor residual disease in blood cancers. Clinical testing and biopharmaceutical drug-development applications make MRD the company’s principal commercial engine.
Immune Medicine
Adaptive also applies its platform to characterize immune responses and identify disease-specific immune signatures. This business supports biopharmaceutical partnerships and longer-term diagnostic and therapeutic opportunities in cancer and autoimmune disease.
Future catalysts
Adaptive still has a clean platform story in immune-system diagnostics and therapeutics, but the commercial side is where the company has to keep proving itself. The update is less about one binary event and more about whether the core immune products continue to move from scientific capability into routine clinical use.
Recent news
- 01
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
Source: Adaptive Biotechnologies
- 02
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
Source: Adaptive Biotechnologies
- 03
Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial
Source: Adaptive Biotechnologies
- 04
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Source: Adaptive Biotechnologies
- 05
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
Source: Adaptive Biotechnologies
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Adaptive Biotechnologies (ADPT)?
Adaptive Biotechnologies (ADPT) most recently closed at 23.60 USD, a -4.07% move versus the previous session.
What is the market cap of Adaptive Biotechnologies (ADPT)?
Adaptive Biotechnologies currently has a market capitalization of 2.42B USD on BioPharmSignal.
What does Adaptive Biotechnologies do?
Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The company’s commercial MRD...
On which exchange is ADPT stock listed?
Adaptive Biotechnologies (ADPT) is associated with NASDAQ, United States, MedTech.
What is Adaptive?
Adaptive still has a clean platform story in immune-system diagnostics and therapeutics, but the commercial side is where the company has to keep proving itself.
Which conditions is Adaptive Biotechnologies targeting with Adaptive?
Adaptive Biotechnologies is associated with cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Adaptive Biotechnologies describe recent progress with Adaptive?
Adaptive still has a clean platform story in immune-system diagnostics and therapeutics, but the commercial side is where the company has to keep proving itself.
What is Immune-System?
Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system.